Assessment of cardiovascular (CV) toxicity by providers in advanced prostate cancer (PCa) patients (pts) on novel hormonal therapy (NHT). This is an ASCO Meeting Abstract from the 2025 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback